Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (CP2D) | Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (CP2D) [Haemonetics Corporation] | BioPortfolio

13:13 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

For use with Haemonetics Apheresis Devices Rx Only

Products: Anticoagulant Citrate Phosphate Double Dextrose (CP2D) and Additive Solution Formula 3 (AS-3)

Company: Haemonetics Corporation 400 Wood Road Braintree, MA 02184

The Haemonetics 250mL Anticoagulant Citrate Phosphate Double Dextrose (CP2D) and 250mL Additive Solution Formula 3 (AS-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. The anticoagulant solution is metered by the apheresis machine into the collected whole blood. It is not to be infused directly into the donor. After the anticoagulant is used, the bag in which it was contained is discarded. When collecting plasma in the RBCP protocol, the plasma is collected into an empty plasma collection bag. One hundred milliliters (100ml) of AS-3 is transferred into one RBC collection bag when using the RBCP protocol or 2 separate bags when using the 2RBC protocol. AS-3 solution provides nutrients to keep the red blood cells viable for 42 days when refrigerated.

CP2D is also indicated for the collection of FFP and PF24 plasma, collected and stored plasma collected using the 822, 822-2P and 822F-2P disposable sets may be frozen within 8 hours (FFP) or within 24 hours which includes 8 hours room temperature storage and 16 hours refrigeration storage (PF24).

The 300mL AS-3 is used in conjunction with automated red blood cell washing devices. AS-3 serves as the nutrient solution for storage of the red blood cell product after deglycerolization. The red blood cells are washed using the Model 215 System. AS-3 is used for priming the disposable and for the last wash of the red blood cells. The washed cells are then re-suspended in 100mL of the AS-3 before transfer into a product collection bag or storage bag. Additive Solution Formula 3 (AS-3) provides nutrients to keep the washed red blood cells viable for up to 14 days after washing when refrigerated.

Neither the CP2D nor the AS-3 container is used for the storage of blood or blood components.

The container for all CP2D and AS-3 solutions is a flexible polyvinyl chloride (PVC) bag sized for holding the appropriate amount of solution. The bag has a single port that is used for bag filling. The port is sealed after filling with a male luer assembly (CP2D) or female luer assembly (AS-3). Both the male and female luers are gamma irradiated prior to use. The plastic bag is contained in an overwrap which is added prior to sterilization.

The formulations for these products are as follows:

Citrate Phosphate Double Dextrose Solution (CP2D) Each 100 mL contains: Citric Acid (Monohydrate), USP 0.327 g Sodium Citrate (Dihydrate), USP 2.630 g Monobasic Sodium Phosphate (Monohydrate), USP 0.222 g Dextrose (Anhydrous), USP 4.640 g

Additive Solution 3 (AS-3) Each 100mL contains: Citric Acid (Monohydrate), USP 0.042 g Monobasic Sodium Phosphate (Monohydrate), USP 0.276 g Sodium Chloride, USP 0.410 g Adenine, USP 0.030 g Dextrose (Anhydrous), USP 1.000 g Sodium Citrate (Dihydrate), USP 0.588 g containing 15 mEq of Sodium.

CP2D Anticoagulant Solution and AS-3 Solution may be used with Haemonetics apheresis devices. See the Haemonetics Operation Manual for full operating instructions.

Prior to use of the solutions, check the solutions for leaks by squeezing each of the bags firmly. If leaks are found, discard the solution.

Studies of the effectiveness of 250mL CP2D and 250mL AS-3 made by Haemonetics Corporation Union, South Carolina facility included in vivo survival data in healthy subjects at one test site and in vitro characterization of stored red blood cells at three test sites.

Haemonetics Clinical Evaluation #95012, involved autologous in vivo recovery and survival studies, and in vitro red blood cell characterization conducted at a single site. RBC results collected with Haemonetics CP2D/AS-3 were compared to crossover controls of manually collected RBCs from the same donors using CP2D/AS-3 made by Medsep Corporation (crossover manual controls). In addition, results were compared to data from other RBC apheresis donors using CP2D/AS-3 solutions manufactured by MedSep (unmatched apheresis controls). Test parameters included hematocrit, hemoglobin, RBC and WBC counts, ATP levels, pH, supernatant potassium, free hemoglobin, supernatant glucose levels, and product weight. The RBC quality of test units after 42-day storage was equivalent or slightly superior to those of the control units. RBCs collected by the two different collection protocols (Red Blood Cells with or without Plasma) showed no significant differences in terms of RBC quality and red blood cells from all groups met FDA and AABB guidelines for 24-hour recovering at 42 days storage.

Study #98001 was performed using 250mL CP2D and 250mL AS-3 to confirm, in vitro, the results of Clinical Evaluation #95012. Three test sites each performed three RBCP and three 2RBC apheresis procedures using the MCS+ LN8150 and associated collection sets. In addition, each site collected six manual whole blood units as concurrent (unmatched) controls using Medsep sets and prepared RBCs according to standard procedures.

In vitro tests of red blood cell functional and physical integrity were conducted at Days 0 and 42 of storage. All plasma units from the RBCP and manual procedures were evaluated on Day 0 for in vitro product characteristics. Group t-tests (two tailed) were performed to examine any statistically significant differences between the properties of apheresis and manual RBCs. Statistically significant differences (p

The results from this study confirmed the observations from Clinical Evaluation #95012. The quality of stored RBC products collected by apheresis is similar to RBC products collected manually. A difference in ATP and hemolysis levels, both after processing and on day 42 of storage, for the apheresis units were not statistically significant when compared to ATP and hemolysis levels from manually collected RBCs and were similar to historicai reference values.

AS-3 300ml was used in conjunction with an automated closed system, the Haemonetics Model 215 (now called the ACP) in Clinical Evaluation #97002. Five test sites were used in this study. 100 samples were tested in vitro and 30 in vivo. Red blood cells derived from CPDA-1 whole blood units were used. AS-1 red blood cells were used as a control. A total of 140 red blood cell units were glycerolized and deglycerolized. The in vitro RBC quality and in vivo RBC viability data obtained on these units demonstrate that red cell units glycerolized and deglycerolized using the Model 215 System and resuspended in 300ml AS-3 solution manufactured by Haemonetics, Union, South Carolina are processed in a closed system and can be stored for 15 days at 4°C.

Clinical report TR-CLN-100229-A was conducted to support the use of CP2D for the collection of FFP and PF24 {plasma collected and stored Plasma collected using the 822, 822-2P and 822F-2P disposable sets may be frozen within 8 hours (FFP) or within 24 hours which includes 8 hours room temperature storage and 16 hours refrigeration storage (PF24). The following tables provide a summary of the results of this evaluation.

Note: Table 1, Table 2, and Table 3 below demonstrate the results of a clinical study conducted for various coagulation factors on plasma that was frozen within 8 hours (FPP) versus plasma frozen within 24 hours, which includes 8 hours room temperature storage and 16 hours refrigeration storage (PF24).

As noted in Table 1 below, Significant differences were observed between PF24 and FFP for assays Prothrombine Time, Partial Thromboplastin Time, FVlla, and FVIII. Table 2 provides the results for Plasma Sample A, which was an outlier and subsequently excluded from the analysis.

Table 3 provides a summary of how many samples tested in each group differed by >20% when FFP and PF24 were compared.

*Sample size = 58. The outlier pair was excluded from the analysis based on the statistical criteria or laboratory errors.

One sample (Plasma Sample A) showed significantly increased levels for Factor VIIa and F1.2. Another sample (Plasma Sample B) showed significantly decreased level of Factor VIII:C for the FFP sample (Table 2). These data were excluded from Table 1 since the values for VIIa and F1.2 were more than 4 SD from the mean. The factor VIII:C was not more than 4 SD from the mean but was significantly lower in FFP as compared to PF24. While other parameters in this sample did not show significant differences when compared to the control FFP, the FDA could not exclude the possibility that the activation found in the PF24 sample was related to the preparation procedure. The rate of such event occurrence was unknown and, based on review of published values for PF24 products, is most likely very rare. The clinical significance of the elevated markers of clotting activation for transfusion recipients is undetermined.

Note: Plasma collected may be labeled as FFP or Plasma Frozen within 24 Hours (PF24).

Note: For FFP, the plasma should be placed in a freezer within 8 hours from the completion of collection. The plasma should be frozen at -18°C or colder. For product intended to be labeled as PF24, the plasma should be refrigerated within 8 hours of collection at 1 – 6°C and frozen within 24 hours of collection. FFP and PF24 should be frozen at -18°C or colder.

Table 1, Summary of FFP and PFZ4 plasma product assays (N=59)
Assay Mean (SD) Median (Min, Max) Mean difference (PF24, FFP) (95% confidence interval)
Prothrombin Time (sec) 12.0 (0.50) 12.1 (0.59) 11.9 12.1 (11.2, 13.8) (10.5, 14.0) 015 (0.09,0.20)
Activated Partial
Time (sec)
29.4 (3.32) 30.3
28.8 29.8 (23.1, 38.5) (24.1, 39.5) 0.86 (0.64, 1.08)
Favtor V (%) 120.1 (23.93) 120.0 (23.88) 120.0 120.0 (61.0, 181.0) (59.0, 182.0) -0.14 (-2.03, 1.76)
Factor Vlla
60.5 (26.95) 45.0 (24.72) 54.0 41.5 (21.0, 131.0) (12.0, 159.0) -15 .50 (-19 .23, -11.77)
Factor VIII:C (%)* 94.3 (34.24) 81.7 (27.31) 88.5 82.5 (33.0, 194.0) (34.0, 152.0) -12.67 (-15.97, -9.38)
AT-III (%) 97.8 (12.24) 94.7 (15.97) 98.0 95.0 (71.0, 126.0) (19.0, 134.0) -3.05 (-6.30, 0.20)
Factor XI (%) 112.2 (17.42) 112.8 (18.46) 113.0 113.0 (81.0,151.0) (82.0, 155.0) 0.63 (-0.70,1.95)
vWF (R:Co)
(% function)
89.5 (35.65) 89.4 (35.58) 85.0 87.0 (35.0, 179.0) (37.0, 185.0) -0.15 (-2.21, 1.91)
Protein S (% activity) 74.9 (19.61) 73.4 (20.76) 72.0 71.0 (33.0, 125.0) (39.0, 126.0) -1.49 (-3.81, 0.83)
Protein C
(% activity)
117.1 (17.59) 117.7 (17.49) 115.0 118.0 (65.0,157.0) (68.0, 162.0) 0.53 (-0.54,1.59)
Fibrinopeptide F 1.2 (pmol/L)* 136.4 (63.34) 133.1 (55.15) 113.0 114.0 (80.0, 344.0) (80.0,331.0) -3.29 (-8.37,1.78)
Thrombln-Anti- thrombin Complex (ng/mL) 2.3 (1.38) 2.1 (0.40) 2.0 2.0 (2.0, 12.4) (2.0,4.8) -0.17 (-0 .53, 0.18)
Table 2, Three outlier pairs in plasma measurements
Subject # Measurement FFP PF24 Range without the outliers
FFP Max PF24 Min PF24 Max
RBCP16 Factor FVIIa (mU/mL) 220 767 21 131 12 159
RBCP16 F1.2 (pmol/L) 702 1940 80 344 80 331
RBCP01 Factor VIII: C(%) 2 63 33 194 34 152
Table 3, Proportion of Paired Sample:PF24 is greater than or less than FFP by more than 20%
Assay PFZ4>FFP by more
than 20%
PF24<FFP by more
than 20%
 Prothrombine Time (sec)  0% (0/59)  0% (0/59)
 Partial Thromboplastin Time (sed  0% (0/59)  0% (0/59)
 Factor V (%)  1.7% (1/59)  0% (0/59)
 Factor Vila (mU/mL)  3.4% (2/58)  89.7% (52/58)
 AT-III (%)  1.7% (1/59)  8.5% (5/59)
 Factor VIII :C (%)  1.7% (1/58)  22.4% (13/58)
 Factor XI (%)  0% (0/59)  0% (0/59)
 Fibrinopeptide 1.2 (pmol/L)  0%(0/58)  1.7% (1/58)
 Protein C (% activity)  0% (0/59)  0% (0/59)
 Protein S (% activity)  5.1% (3/59)  1.7% (1/59)
 Thrombin-Antithrombin Complex (ng/mL)  1.7% (1/59)  3.4% (2/59)
vWF (% activity) 3.4% (2/59) 1.7% (1/59)

Contraindications: None known

Precautions for use: • Solutions are NOT INTENDED FOR DIRECT INFUSION. • Do not use if particulate matter is present or if the solution is cloudy Note: Some opacity of the plastic container due to moisture absorbance by the PVC during the sterilization process may be observed. This is normal and does not affect the quality or the safety of the product. This white, hazy appearance will diminish gradually over time. This advice only applies to the plastic container. Do not use if the solution itself is cloudy or contains particulate matter. •Do not use if the container is damaged, leaking or if there is any visible sign of deterioration. Note: The over wrap serves as a moisture barrier. Upon removing the solution bag, small droplets of condensation may be present in the packaging. This is considered normal. After removing the over wrap gently squeeze the inner bag which protects the sterility of the solution. Discard if any leaks are observed or if an excessive amount of solution is noted within the over wrap. • Do not reuse solution. Discard any unused or partially used solutions. • Protect from sharp objects. • Verify that solutions have been appropriately connected to avoid leaks. • The set should be loaded and primed for use within 8 hours of the start of the collection. • Carry out the apheresis procedure in accordance with the detailed instructions of the manufacturer of the apheresis device.

Donors being reinfused with citrated blood or blood components may experience side effects due to the presence of citrate. Patients being transfused with the blood components could also experience a reaction to the citrated blood components. The major symptom experienced by donors is paraesthesia. Should this occur the reinfusion should be stopped or the reinfusion rate decreased. In the event of inadvertent bolus of the product administer calcium gluconate.

Both solutions are intended to be used only with automated apheresis devices for collecting human blood and blood components. CP2D is used as an anticoagulant solution and AS-3 is intended for use a nutrient solution. Neither solution is intended for direct infusion; neither solution produces a pharmacological effect.

Both solutions are intended to be used only with automated apheresis devices for collecting human blood and blood components. CP2D is used as an anticoagulant solution and AS-3 is intended for use a nutrient solution. Neither solution is intended for direct infusion.

250mL CP2D Anticoagulant Solution is supplied in flexible PVC containers with a sterile, non-pyrogenic fluid path. 250mL and 300mL AS-3 Nutrient Solution is supplied in flexible PVC containers with a sterile, non-pyrogenic fluid path.

Room temperature (25°C/77°F). Avoid excessive heat. Protect from freezing.



Intended for use only with automated red cell apheresis devices to collect red blood cells and plasma (FFP and PF24). See the appropriate Operator’s manual for additional information and complete usage instructions.

Each 100 mL contains: Citric Acid (Monohydrate), USP                                      0.327 g Sodium Citrate (Dihydrate), USP                                   2.630 g Monobasic Sodium Phosphate (Monohydrate), USP      0.222 g Dextrose (Anhydrous), USP                                           4.640 g

CAUTION: Not for direct intravenous infusion. The pouch is a moisture barrier. Do not use unless solution is clear and no leaks detected. Single use container. Discard unused portion. Sterile, nonpyrogenic fluid path. Rx Only

RECOMENDED STORAGE: Room Temperature (25°C / 77°F) Avoid excessive heat. Protect from freezing.

L065 DA                                      Product code 455A Haemonetics Corporation           Lot No. Braintree, MA 02184 USA            Exp Date


Haemonetics Corporation

Active Ingredients


Clinical Trials [5062 Associated Clinical Trials listed on BioPortfolio]

Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes (HECICS)

The primary aim of this randomized controlled study is to determine whether the use Anticoagulant Citrate Dextrose Solution--Formula A (ACD-A) in cell salvage reduces inflammation and oxid...

The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients

Acetate-free citrate containing dialysate is expected to be clinically effective in maintaining hemodynamic stability during hemodialysis (HD). It has been demonstrated that citrate dialys...

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye

The purpose of this study is to assess the safety and efficacy of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patie...

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patie...

Bundang Rehabilitative Impact Study of the Elbow Epicondylitis

This study is to assess the safety and effect of polydeoxyribonucleotide(PDRN) on the lateral epicondylitis with ultrasonography-guided injection of the PDRN or dextrose solution. C...

PubMed Articles [8058 Associated PubMed Articles listed on BioPortfolio]

Sodium citrate contributes to the platelet storage lesion.

Sodium citrate has become the preferred anticoagulant used for apheresis collection and has been included in commercial platelet additive solutions (PASs) since PAS-II. It was suggested that citrate b...

Haematological and morphological evaluation of feline whole blood units collected for transfusion purposes.

Objectives Despite the increasing availability of feline blood collected and stored for transfusion purposes, few studies have been performed on feline blood units. The aim of this prospective in vitr...

A randomized controlled clinical trial of 4% sodium citrate versus heparin as locking solution for temporary dialysis catheters among hemodialysis patients

Limited reports are available on the role of 4% citrate as a locking solution for temporary dialysis catheters. Hence, the aim of this study is to investigate the role of 4% citrate vs. heparin 5,000 ...

Efficient capture of phosphate from aqueous solution using acid activated akadama clay and mechanisms analysis.

In this study, akadama clay, a kind of volcano ash, was activated with sulfuric acid and then evaluated for the adsorption of phosphate from aqueous solution via batch experiments. The effects of adso...

The application of forward osmosis for simulated surface water treatment by using trisodium citrate as draw solute.

In this study, trisodium citrate was used as draw solute in forward osmosis (FO) due to its biodegradability and easy reuse after FO dilution. The effect of operating conditions on FO performance was ...

Quick Search


Relevant Topics

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record